DKMS Oct 6 2025 The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts. The first results of the ASAP study (ASAP standing for "as soon as possible"), published in 2024, have already attracted considerable attention. ASAP questions existing treatment standards for AML and was the first randomized controlled trial to compare remission induction with salvage chemotherapy prior to allo-HSCT – which represents the